373 related articles for article (PubMed ID: 25826649)
1. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response.
Acheson DT; Feifel D; Kamenski M; Mckinney R; Risbrough VB
Depress Anxiety; 2015 Jun; 32(6):400-7. PubMed ID: 25826649
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids enhance in vivo exposure-based therapy of spider phobia.
Soravia LM; Heinrichs M; Winzeler L; Fisler M; Schmitt W; Horn H; Dierks T; Strik W; Hofmann SG; de Quervain DJ
Depress Anxiety; 2014 May; 31(5):429-35. PubMed ID: 24265104
[TBL] [Abstract][Full Text] [Related]
3. Post-exposure cortisol administration does not augment the success of exposure therapy: A randomized placebo-controlled study.
Raeder F; Merz CJ; Tegenthoff M; Wolf OT; Margraf J; Zlomuzica A
Psychoneuroendocrinology; 2019 Jan; 99():174-182. PubMed ID: 30245330
[TBL] [Abstract][Full Text] [Related]
4. D-cycloserine enhances generalization of fear extinction in children.
Byrne SP; Rapee RM; Richardson R; Malhi GS; Jones M; Hudson JL
Depress Anxiety; 2015 Jun; 32(6):408-14. PubMed ID: 25775435
[TBL] [Abstract][Full Text] [Related]
5. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
Ressler KJ; Rothbaum BO; Tannenbaum L; Anderson P; Graap K; Zimand E; Hodges L; Davis M
Arch Gen Psychiatry; 2004 Nov; 61(11):1136-44. PubMed ID: 15520361
[TBL] [Abstract][Full Text] [Related]
6. Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding.
Russell J; Maguire S; Hunt GE; Kesby A; Suraev A; Stuart J; Booth J; McGregor IS
Psychoneuroendocrinology; 2018 Jan; 87():83-92. PubMed ID: 29049935
[TBL] [Abstract][Full Text] [Related]
7. Intranasal oxytocin as strategy for medication-enhanced psychotherapy of PTSD: salience processing and fear inhibition processes.
Koch SB; van Zuiden M; Nawijn L; Frijling JL; Veltman DJ; Olff M
Psychoneuroendocrinology; 2014 Feb; 40():242-56. PubMed ID: 24485496
[TBL] [Abstract][Full Text] [Related]
8. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample.
Acheson D; Feifel D; de Wilde S; McKinney R; Lohr J; Risbrough V
Psychopharmacology (Berl); 2013 Sep; 229(1):199-208. PubMed ID: 23644911
[TBL] [Abstract][Full Text] [Related]
9. Brain-based mediation of non-conscious reduction of phobic avoidance in young women during functional MRI: a randomised controlled experiment.
Siegel P; Wang Z; Murray L; Campos J; Sims V; Leighton E; Peterson BS
Lancet Psychiatry; 2020 Nov; 7(11):971-981. PubMed ID: 33069319
[TBL] [Abstract][Full Text] [Related]
10. Post-retrieval oxytocin facilitates next day extinction of threat memory in humans.
Hu J; Wang Z; Feng X; Long C; Schiller D
Psychopharmacology (Berl); 2019 Jan; 236(1):293-301. PubMed ID: 30370450
[TBL] [Abstract][Full Text] [Related]
11. Hydrocortisone as an adjunct to brief cognitive-behavioural therapy for specific fear: Endocrine and cognitive biomarkers as predictors of symptom improvement.
Steudte-Schmiedgen S; Fay E; Capitao L; Kirschbaum C; Reinecke A
J Psychopharmacol; 2021 Jun; 35(6):641-651. PubMed ID: 33908295
[TBL] [Abstract][Full Text] [Related]
12. D-cycloserine as adjunct to brief computerised CBT for spider fear: Effects on fear, behaviour, and cognitive biases.
Kappelmann N; Suesse M; Steudte-Schmiedgen S; Kaldewaij R; Browning M; Michael T; Rinck M; Reinecke A
J Behav Ther Exp Psychiatry; 2020 Sep; 68():101546. PubMed ID: 31951819
[TBL] [Abstract][Full Text] [Related]
13. Delaying in vivo exposure to a tarantula with very brief exposure to phobic stimuli.
Siegel P; Gallagher KA
J Behav Ther Exp Psychiatry; 2015 Mar; 46():182-8. PubMed ID: 25460265
[TBL] [Abstract][Full Text] [Related]
14. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression.
MacDonald K; MacDonald TM; Brüne M; Lamb K; Wilson MP; Golshan S; Feifel D
Psychoneuroendocrinology; 2013 Dec; 38(12):2831-43. PubMed ID: 23810433
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.
van der Flier FE; Kwee CMB; Cath DC; Batelaan NM; Groenink L; Duits P; van der Veen DC; van Balkom AJLM; Baas JMP
BMC Psychiatry; 2019 Feb; 19(1):69. PubMed ID: 30760241
[TBL] [Abstract][Full Text] [Related]
16. Endogenous cortisol levels influence exposure therapy in spider phobia.
Lass-Hennemann J; Michael T
Behav Res Ther; 2014 Sep; 60():39-45. PubMed ID: 25051297
[TBL] [Abstract][Full Text] [Related]
17. Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial.
Flanagan JC; Sippel LM; Wahlquist A; Moran-Santa Maria MM; Back SE
J Psychiatr Res; 2018 Mar; 98():64-69. PubMed ID: 29294429
[TBL] [Abstract][Full Text] [Related]
18. Virtual reality exposure therapy for fear of spiders: an open trial and feasibility study of a new treatment for arachnophobia.
Andersson J; Hallin J; Tingström A; Knutsson J
Nord J Psychiatry; 2024 Feb; 78(2):128-136. PubMed ID: 38295831
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
Hofmann SG; Meuret AE; Smits JA; Simon NM; Pollack MH; Eisenmenger K; Shiekh M; Otto MW
Arch Gen Psychiatry; 2006 Mar; 63(3):298-304. PubMed ID: 16520435
[TBL] [Abstract][Full Text] [Related]
20. Intranasal oxytocin decreases fear generalization in males, but does not modulate discrimination threshold.
Dou H; Zou L; Becker B; Lei Y
Psychopharmacology (Berl); 2021 Mar; 238(3):677-689. PubMed ID: 33241482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
